| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
WHO Collaborating Center for Research on Primary Prevention of Cardiovascular Diseases, Kyoto (Y.Y.)
Fujicco Co., Ltd., Kobe (T.T., Y.F., K.H., M.F.)
Department of Life Long Health Promotion Faculty of Education, University of the Ryukyus, Nishihara (A.M., K.T.)
Division of Life Science, Graduate School of Integrate Science and Art University of East Asia, Shimonoseki (Y.N.), JAPAN
Institute of Geriatrics and Gerontology, Pontifical Catholic University of Rio Grande do Sul, Rio de Janeiro, BRAZIL (E.M., Y.M.)
Address reprint requests to: Yukio Yamori MD, PhD, FACN, WHO Collaborating Center for Research on Primary Prevention of Cardiovascular Diseases, Kokusaikenju Bldg, 86, Shimobanba-cho, Joudoji, Sakyo-ku, Kyoto 6068431, JAPAN. E-mail: Yukio.Yamori{at}ma3.seikyou.ne.jp
Objective: Some human studies and animal models of experimental osteoporosis have shown that soy isoflavones may be effective on bone health. In this study, we carried out an intervention study to explore the effects of dietary isoflavone on bone metabolism.
Methods: Forty healthy female postmenopausal Japanese immigrants living in Brazil were divided into two groups: isoflavone-administered (n = 20) or placebo (n = 20). Subjects in the isoflavone-administered group ingested 37.3 mg per day for 10 weeks. The collection of 24-hour urine and the measurement of bone stiffness were performed at 0 and 10 weeks. Urinary excretion of isoflavones and bone resorption markers were analyzed.
Results: Urinary isoflavone excretion in the isoflavone-administered group was significantly increased at weeks 3 and 10. Urinary excretion of bone resorption markers was reduced in the isoflavone-administered group, while the placebo group did not show any significant reduction. Differences in levels of urinary isoflavones and bone resorption markers between the two groups were significant.
Conclusion: This study demonstrated that the bone resorption was associated with the intake of soy isoflavones in postmenopausal women, and continuous dietary intake of isoflavone may inhibit postmenopausal osteoporosis.
Key words: isoflavones, bone resorption, pyridinoline, deoxypyridinoline, postmenopausal women
This article has been cited by other articles:
|
|
 |
|
  D. Bunout, G. Barrera, L. Leiva, V. Gattas, M. P. de la Maza, F. Haschke, P. Steenhout, P. Klassen, C. Hager, E. Offord, et al. Effect of a Nutritional Supplementation on Bone Health in Chilean Elderly Subjects with Femoral Osteoporosis J. Am. Coll. Nutr., June 1, 2006; 25(3): 170 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ikeda, M. Iki, A. Morita, E. Kajita, S. Kagamimori, Y. Kagawa, and H. Yoneshima Intake of Fermented Soybeans, Natto, Is Associated with Reduced Bone Loss in Postmenopausal Women: Japanese Population-Based Osteoporosis (JPOS) Study J. Nutr., May 1, 2006; 136(5): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Sacks, A. Lichtenstein, L. Van Horn, W. Harris, P. Kris-Etherton, M. Winston, and for the American Heart Association Nutrition Commi Soy Protein, Isoflavones, and Cardiovascular Health: An American Heart Association Science Advisory for Professionals From the Nutrition Committee Circulation, February 21, 2006; 113(7): 1034 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Williamson and C. Manach Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies Am. J. Clinical Nutrition, January 1, 2005; 81(1): 243S - 255S. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
